Characterization of human immunodeficiency virus type 1 Vif particle incorporation.

PubWeight™: 1.69‹?› | Rank: Top 3%

🔗 View Article (PMC 190632)

Published in J Virol on September 01, 1996

Authors

D Camaur1, D Trono

Author Affiliations

1: Infectious Disease Laboratory, Salk Institute for Biological Studies, La Jolla, California 92037, USA.

Articles citing this

Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J Virol (1999) 2.66

The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol (1997) 2.39

The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission. EMBO J (1998) 2.37

Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 2.35

Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol (2004) 2.27

Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol (2001) 2.16

Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol (1999) 2.16

Coupled integration of human immunodeficiency virus type 1 cDNA ends by purified integrase in vitro: stimulation by the viral nucleocapsid protein. J Virol (1999) 2.13

Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol (2000) 2.11

Kinetic analysis of human immunodeficiency virus type 1 assembly reveals the presence of sequential intermediates. J Virol (2000) 2.11

Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol (1996) 1.76

Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J Virol (1998) 1.73

Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription. J Virol (2000) 1.60

Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor. J Virol (1997) 1.55

Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J Virol (1999) 1.52

Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol (2003) 1.49

Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol (2003) 1.41

Role of Vif in stability of the human immunodeficiency virus type 1 core. J Virol (2000) 1.34

The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity. J Virol (1998) 1.32

Mutations in the N-terminal domain of human immunodeficiency virus type 1 nucleocapsid protein affect virion core structure and proviral DNA synthesis. J Virol (1997) 1.31

A human nuclear shuttling protein that interacts with human immunodeficiency virus type 1 matrix is packaged into virions. J Virol (2000) 1.16

Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev (2009) 1.12

HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med (2010) 1.03

Advances in the structural understanding of Vif proteins. Curr HIV Res (2008) 1.03

Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front Microbiol (2014) 1.00

Productive replication of Vif-chimeric HIV-1 in feline cells. J Virol (2010) 0.99

Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions. J Virol (1999) 0.98

Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J Virol (1997) 0.94

Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif. J Mol Biol (2011) 0.93

Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc Natl Acad Sci U S A (1997) 0.92

Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function. J Virol (2002) 0.91

Feline immunodeficiency virus Vif localizes to the nucleus. J Virol (2000) 0.90

Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr. J Virol (2000) 0.90

Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins. J Virol (1998) 0.88

Molecular structure and biochemical properties of the HCCH-Zn2+ site in HIV-1 Vif. Biochemistry (2009) 0.85

HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G. J Biol Chem (2013) 0.84

Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag. J Virol (2001) 0.83

NF-IL6 (C/EBPbeta) induces HIV-1 replication by inhibiting cytidine deaminase APOBEC3G. Proc Natl Acad Sci U S A (2008) 0.82

Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging. J Virol (2001) 0.82

HIV-1 Vif: a guardian of the virus that opens up a new era in the research field of restriction factors. Front Microbiol (2013) 0.80

Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail. RNA Biol (2014) 0.78

Isolation and characterization of human cells resistant to retrovirus infection. Retrovirology (2007) 0.78

Conserved Interaction of Lentiviral Vif Molecules with HIV-1 Gag and Differential Effects of Species-Specific Vif on Virus Production. J Virol (2017) 0.75

Articles cited by this

Nucleotide sequence of the AIDS virus, LAV. Cell (1985) 16.81

Genome organization and transactivation of the human immunodeficiency virus type 2. Nature (1987) 11.79

Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (1990) 10.13

Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A (1988) 9.35

Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. Nature (1987) 7.96

The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51

The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16

Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol (1989) 6.11

Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11

Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85

Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J Virol (1991) 5.49

Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol (1993) 5.30

Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 4.57

Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol (1995) 4.45

HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell (1995) 4.41

Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. J Virol (1991) 3.72

Two dominant-acting selectable markers for gene transfer studies in mammalian cells. Proc Natl Acad Sci U S A (1988) 3.21

Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol (1993) 3.12

Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J Virol (1991) 3.05

Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol (1993) 3.01

Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products. J Virol (1991) 2.62

Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol (1995) 2.45

Expression of human immunodeficiency virus type 1 vif and vpr mRNAs is Rev-dependent and regulated by splicing. Virology (1991) 2.43

Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes (1992) 2.40

Nucleotide sequence and genome organization of biologically active proviruses of the bovine immunodeficiency-like virus. Virology (1990) 2.36

Subcellular localization of the Vif protein of human immunodeficiency virus type 1. J Virol (1994) 2.35

Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infectious virus. Virology (1990) 2.33

Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J Virol (1996) 2.30

The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J Virol (1995) 2.25

Cell-free transmission of Vif mutants of HIV-1. Virology (1992) 2.13

Role of vif during packing of the core of HIV-1. Virology (1994) 2.01

Biological characterization of human immunodeficiency virus type 1 and type 2 mutants in human peripheral blood mononuclear cells. Arch Virol (1992) 1.81

Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. J Virol (1995) 1.36

The human immunodeficiency virus type 1 (HIV-1) vif protein is located in the cytoplasm of infected cells and its effect on viral replication is equivalent in HIV-2. AIDS Res Hum Retroviruses (1993) 1.23

In vivo genetic variability of the HIV-1 vif gene. Virology (1994) 1.18

Effect of reciprocal complementation of two defective human immunodeficiency virus type 1 (HIV-1) molecular clones on HIV-1 cell tropism and virulence. J Virol (1992) 1.10

Articles by these authors

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 28.95

A third-generation lentivirus vector with a conditional packaging system. J Virol (1998) 16.07

Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol (1997) 12.11

Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A (1996) 9.15

Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol (1998) 8.21

Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11

Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell (1994) 5.92

Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol (1999) 5.35

Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell (1990) 4.78

HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci U S A (1997) 4.59

Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol (1995) 4.45

HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell (1995) 4.41

HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell (1995) 4.25

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science (2000) 3.89

The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci U S A (1994) 3.65

Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol (1997) 3.37

Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol (1999) 2.97

HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat Cell Biol (2000) 2.95

Nef-induced CD4 degradation: a diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes. Cell (1999) 2.89

Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol (1996) 2.72

Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication. Mol Cell (2001) 2.53

The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci U S A (2000) 2.42

Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression. J Exp Med (1990) 2.28

Mechanism of Nef-induced CD4 endocytosis: Nef connects CD4 with the mu chain of adaptor complexes. EMBO J (1998) 2.25

Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking. J Virol (1999) 2.25

Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene (1995) 2.05

The plasma membrane as a combat zone in the HIV battlefield. Genes Dev (2000) 2.02

Substitutions in the protease (3Cpro) gene of poliovirus can suppress a mutation in the 5' noncoding region. J Virol (1990) 1.96

Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Ther (2000) 1.81

The HIV-1 Nef protein acts as a connector with sorting pathways in the Golgi and at the plasma membrane. Immunity (1997) 1.78

The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors. Immunol Rev (1999) 1.77

Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 1.76

Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency. J Virol (1992) 1.74

High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood (2000) 1.63

Genomic instability in induced stem cells. Cell Death Differ (2011) 1.63

Mutational analysis of HIV-1 Nef: identification of two mutants that are temperature-sensitive for CD4 downregulation. Virology (1996) 1.56

The Nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix. J Virol (1997) 1.52

Reversible immortalization of human primary cells by lentivector-mediated transfer of specific genes. Mol Ther (2000) 1.48

A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol Ther (2000) 1.43

Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro. J Virol (2000) 1.38

Nef-mediated clathrin-coated pit formation. J Cell Biol (1997) 1.38

The blocks to human immunodeficiency virus type 1 Tat and Rev functions in mouse cell lines are independent. J Virol (1993) 1.34

The Nef protein of primate lentiviruses. Rev Med Virol (1999) 1.34

The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity. J Virol (1998) 1.32

HIV-1 latency due to the site of proviral integration. Virology (1993) 1.23

Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum Gene Ther (2000) 1.14

Activity analysis of housekeeping promoters using self-inactivating lentiviral vector delivery into the mouse retina. Gene Ther (2003) 1.07

Sequential trisomization of chromosomes 6 and 7 in mouse skin premalignant lesions. Mol Carcinog (1989) 1.06

Ectopic expression of the beta-cell specific transcription factor Pdx1 inhibits glucagon gene transcription. Diabetologia (2003) 1.04

Human immunodeficiency virus type 1 matrix protein interacts with cellular protein HO3. J Virol (1998) 1.04

Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther (2001) 1.04

Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells. Blood (2000) 1.03

Alterations of the p53 tumor suppressor gene during mouse skin tumor progression. Cancer Res (1991) 1.02

Transgene expression in the guinea pig cochlea mediated by a lentivirus-derived gene transfer vector. Hum Gene Ther (1999) 1.01

Adult rat liver cells transdifferentiated with lentiviral IPF1 vectors reverse diabetes in mice: an ex vivo gene therapy approach. Diabetologia (2006) 1.01

Applications of gene therapy to the CNS. Hum Mol Genet (1996) 1.00

Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease. Gene Ther (2011) 1.00

Human immunodeficiency virus matrix tyrosine phosphorylation: characterization of the kinase and its substrate requirements. J Virol (1997) 0.99

Deletion of nef slows but does not prevent CD4-positive T-cell depletion in human immunodeficiency virus type 1-infected human-PBL-SCID mice. J Virol (1997) 0.97

Genetic analysis of susceptibility to spontaneous and UV-induced carcinogenesis in Xiphophorus hybrid fish. Mar Biotechnol (NY) (2001) 0.95

In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin. Mol Cell Neurosci (2000) 0.94

Alternative oxidase in durum wheat mitochondria. Activation by pyruvate, hydroxypyruvate and glyoxylate and physiological role. Plant Cell Physiol (2001) 0.94

Peripuberty stress leads to abnormal aggression, altered amygdala and orbitofrontal reactivity and increased prefrontal MAOA gene expression. Transl Psychiatry (2013) 0.94

The use of a recombinant lentiviral vector for ex vivo gene transfer into the rat CNS. Neuroreport (2000) 0.93

Sequential development of aneuploidy, keratin modifications, and gamma-glutamyltransferase expression in mouse skin papillomas. Cancer Res (1988) 0.91

Intracellular immunization: trans-dominant mutants of HIV gene products as tools for the study and interruption of viral replication. AIDS Res Hum Retroviruses (1992) 0.90

Lentivirus-mediated Bcl-2 expression in betaTC-tet cells improves resistance to hypoxia and cytokine-induced apoptosis while preserving in vitro and in vivo control of insulin secretion. Gene Ther (1999) 0.90

Preneoplastic and neoplastic growth of xenotransplanted lung-derived human cell lines using deepithelialized rat tracheas. Cancer Res (1987) 0.90

Treatment of fulminant liver failure by transplantation of microencapsulated primary or immortalized xenogeneic hepatocytes. Transplant Proc (2005) 0.87

Epidermoid metaplasias of xenotransplanted human tracheobronchial epithelium. Carcinogenesis (1986) 0.86

Second-messenger regulation of receptor association with clathrin-coated pits: a novel and selective mechanism in the control of CD4 endocytosis. Mol Biol Cell (1997) 0.86

When accessories turn out to be essential. Nat Med (1998) 0.86

Regulation of apoptosis in uterine leiomyomata. Endocrinology (1997) 0.85

Differential effects of human cytomegalovirus on integrated and unintegrated human immunodeficiency virus sequences. J Virol (1995) 0.85

Genetic therapies for HIV infections: promise for the future. AIDS (1995) 0.85

Transduction of CD34+ cells with lentiviral vectors enables the production of large quantities of transgene-expressing immature and mature dendritic cells. J Gene Med (2001) 0.84

Lentivirus gene transfer in murine hematopoietic progenitor cells is compromised by a delay in proviral integration and results in transduction mosaicism and heterogeneous gene expression in progeny cells. J Virol (2000) 0.84

Lentiviral-mediated gene transfer into haematopoietic stem cells. J Intern Med (2001) 0.84

MNU induction of neoplasia in a platyfish model. Lab Invest (2001) 0.84

Genetic analysis of neoplasia induced by N-nitroso-N-methylurea in Xiphophorus hybrid fish. Mar Biotechnol (NY) (2001) 0.84

A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther (2000) 0.83

The HIV Nef protein alters Ca(2+) signaling in myelomonocytic cells through SH3-mediated protein-protein interactions. J Biol Chem (1999) 0.82

Association of protein kinase C activation with induction of ornithine decarboxylase in murine but not human keratinocyte cultures. Mol Carcinog (1993) 0.80

Lentiviral vectors for the gene therapy of lympho-hematological disorders. Curr Top Microbiol Immunol (2002) 0.80

[Causes of death in cases of lymphoma, myeloma and Hodgkin disease. Study of 218 cases]. Schweiz Med Wochenschr (1983) 0.79

Extraskeletal myxoid chondrosarcoma. A case report with histochemical and ultrastructural features. Appl Pathol (1983) 0.79

HIV-based vectors: getting the best out of the worst. J Gene Med (2000) 0.79

Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles. Pharm Res (2001) 0.78

Living in oblivion: HIV immune evasion. Semin Immunol (2001) 0.78

Lentivirus-mediated gene transfer of gp91phox corrects chronic granulomatous disease (CGD) phenotype in human X-CGD cells. J Gene Med (2001) 0.77

The multifaceted role of HIV Nef. Res Virol (1997) 0.77

Association of rat p15INK4B/p16INK4 deletions with monosomy 5 in kidney epithelial cell lines but not primary renal tumors. Cancer Res (1995) 0.77

Lentiviral vectors for the genetic modification of hematopoietic stem cells. Ernst Schering Res Found Workshop (2001) 0.76

[The application of lentiviral vectors for tissue-specific gene manipulations]. Tsitologiia (2008) 0.76

Xiphophorus genetic linkage map: beginnings of comparative gene mapping in fishes. Mar Biotechnol (NY) (2001) 0.76

[Aggressive therapy in a case of Moschowitz syndrome]. Nouv Rev Fr Hematol (1984) 0.75

Liquorice intoxication caused by alcohol-free pastis. Lancet (1983) 0.75

[Thrombotic thrombocytopenic purpura treated with prostacyclin. Apropos of 2 case reports]. Schweiz Med Wochenschr (1986) 0.75

[Pseudo-Conn's syndrome due to intoxication with nonalcoholic pastis]. Schweiz Med Wochenschr (1983) 0.75